Navigation Links
Two New U.S. Patents Issued to Dyadic International
Date:4/7/2011

JUPITER, Fla., April 7, 2011 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries, announced today that it has been issued U.S. Patent No. 7,906,309 entitled, "Expression-Regulating Sequences and Expression Products in the Field of Filamentous Fungi" and U.S. Patent No. 7,892,812 entitled, "Chrysosporium Cellulase and Methods of Use" by the United States Patent and Trademark Office ("USPTO").

(Logo: http://photos.prnewswire.com/prnh/20091214/DYADICLOGO)

U.S. Patent No. 7,906,309
"Expression-Regulating Sequences and Expression Products in the Field of Filamentous Fungi"

The inventions embodied by this patent are genes and their corresponding enzymes from glycosyl hydrolase family 10 having xylanase activity which are derived from Chysosporium fungal strains. Other related applications claim cellobiohydrolases and glyceraldehyde phosphate dehydrogenases. These enzymes have proven to be effective in breaking down the major component of plant cell walls, commonly known as lignocellulosic biomass, into fermentable C5 sugars which can be used in the production of biofuels and biochemicals.  These genes and enzymes were isolated from Dyadic's patented and proprietary C1 fungus and identified through the genome annotation project conducted by Dyadic in conjunction with Scripps Florida.

Dyadic's President and Chief Executive Officer, Mark Emalfarb, stated, "This patent protects Dyadic's ability to use its C1 technology to make fermentable C5 sugars in addition to the C6 sugars allowed by our previously awarded biofuels patent."

U.S. Patent No. 7,892,812
"Chrysosporium Cellulase and Methods of Use"

The inventions embodied by this patent are industrial uses and novel methods of manufacturing endoglucanases and other groups of neutral or alkaline cellulases that are isolated from Chrysosporium fungal strains. These enzymes work over broader temperature and pH ranges than other commercially available enzymes. Endoglucanases are commercially useful in the processing of cellulose-based materials with applications in the biofuels, biochemicals, beverage, feed, textiles and pulp and paper industries among other potential uses.

These newly issued patents are accessible on the USPTO's website at www.uspto.gov or on Dyadic's website at www.dyadic.com.

These patents are the eighth and ninth U.S. patents issued to Dyadic adding to its portfolio of 74 international patents and more than 33 pending patent applications worldwide which cover various features of Dyadic's proprietary technologies.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzyme and protein products for the bioenergy, industrial enzyme and biopharmaceutical industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 Platform Technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Source Precision Medicine, Inc. d/b/a Source MDx Announces Foundational Patents Will Be Offered for Sale on April 29, 2011
2. Court Rules on First Set of Patents in FENTORA Litigation
3. caprotec bioanalytics Announces Issuance In Europe of All Core Patents of Its CCMS Technology
4. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
5. Cutting Edge Nanotech Patents for Displays, Lighting, X-ray, Medical Imaging, and Diagnostics Available for Sale by ICAP Ocean Tomo
6. Sensipar® Patents Upheld By District Court
7. COPAN Files New Patents Following the Development of High Nucleic Acid Yield Flocked Swabs
8. Interventional Spine®, Inc. Announces Issuance of Key Patents for the PERPOS® PLS System
9. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
10. Volcano Corporation Files Counterclaim Asserting St. Jude Infringes Three Volcano Patents; Answers St. Judes Patent Infringement Claims
11. Amedica® Receives Patents for Innovative Motion-Preserving Total Disc Implant Featuring Silicon Nitride
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
Breaking Medicine News(10 mins):